论文部分内容阅读
20 0 0年 9月欧洲糖尿病研究联合会 (ＥＳＡＤ)在以色列的耶路撒冷召开的会议上 ,报告了一项伍用纳格列奈 (ｎａｔｅｇｌｉｎｉｄｅ,Ｓｔａｒｌｉｘ)与二甲双胍的Ⅲ期临床试验 ,表明能有效地控制Ⅱ型糖尿病 (ＮＩＤＤＭ)血糖水平。口服抗糖尿病药 (ＡＤＤ)纳格列奈是由诺华公司
In a September 2003 meeting of the European Association for the Study of Diabetes (ESAD) in Jerusalem, Israel, a Phase III clinical trial of nateglinide (Starlix) with metformin was reported, indicating that it is effective Control of type 2 diabetes (NIDDM) blood glucose levels. Oral antidiabetic (ADD) nateglinide is manufactured by Novartis